drugset / Trial / NCT04890548

Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure

NCT04890548

Phase 1 Withdrawn AstraZeneca Parexel · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this mechanistic study is to evaluate the vasodilatory effects of AZD3427 in adult patients with heart failure and will be performed at approximately 2 study sites in the United Kingdom.

Timeline

Start
2021-11-23
Primary completion
2022-08-02
Completion
2022-08-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD3427 Unknown Other

Indications